Galapagos N.V.

Price Chart

Risk-Adjusted Performance

Also Listed On

Galapagos N.V. (GLPG) Price Performance

Galapagos N.V. (GLPG) trades on Euronext Amsterdam in EUR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at EUR26.46, down 4.41% from the previous close.

Over the past year, GLPG has traded between a low of EUR21.02 and a high of EUR31.84. The stock has gained 12.0% over this period. It is currently 16.9% below its 52-week high.

Galapagos N.V. has a market capitalization of $1.98B, with a price-to-earnings ratio of 6.17.

About Galapagos N.V.

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.